The Development and validation of few UV Spectrophotometric methods for the determination of Apremilast in bulk form and pharmaceutical dosage form
Apremilast is an analog of thalidomide and used as a medication for the treatment of certain type of psoriasis and psoriatic arthritis. It is pale yellow to white colour powder which is non-hygroscopic and practically insoluble in water and buffer solutions of wide pH range, but is soluble is lipophilic solvents like acetone , acetonitrile , butanone , dichloromethane and tetrahydrofuran. Validation study was performed to develop novel, simple, precise, sensitive and accurate UV spectrophotometric method w for the estimation of Apremilast. Double beam UV-VIS spectrophotometer (UV-1800, Shimadzu, Japan) with a pair of 10mm path length matched quartz cells were used for the study. Method A(methanol), Method B(ethanol), Method C(DMSO), Method D( acetonitrile) were developed foe estimation of Apremilast by zero-order and first-order derivative. Linearity was carried out in the concentration range of 0.2-1.0µg/ml and correlation coefficients were found to be 0.999. The relative standard deviation was found to be <2%. The LOD and LOQ were found to be 0.120µg/ml and 0.7810µg/ml respectively. Hence, the methods were validated according to ICH to guidelines and can be adopted for the routine analysis of Apremilast in pure and table dosage form.
Keywords: Apremilast, UV visible spectrophotometer, zero-order, first-order derivative, ICH guidelines.
2. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: Master regulator of innate immune cell function, Am J Respir Cell Mol Biol, 2008; 39:127-132.
3. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase 4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis, Br J Pharmacol, 2010; 159:842-855.
4. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study, Arthritis Rheum 2012; 64:3156-3167.
5. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast, Curr Med Res Opin, 2008; 24:1529-1538.
6. Wu A, Rohane P, Ng J, DeGroot B, Colgan B, Laskin OL, et al. Safety/tolerability and pharmacokinetics of multiple oral doses of apremilast in healthy male subjects, Clin Pharmacol Ther, 2012; 91:S26.
7. Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, et al. Disposition, metabolism and mass balance of [(14) C] apremilast following oral administration. Xenobiotica, 2011; 41:1063-1075.
8. Wu A, Scheffler M. First-time-in-man, safety/tolerability and pharmacokinetics of ascending oral doses of Apremilast (APR) in healthy subjects (HS). J Invest Dermatol, 2011; 131:S86.
9. Siladitya B, Subhajit G, Fahad A, Saayak S, Sritoma B. UV-Visible Spectropho- tometric Method Development and Validation of Assay of Paracetamol Tablet Formulation, Journal of Analytical and Bioanalytical Techniques 2012; 3(6):1-6.
10. Mohammad A, Sudhir K, Shashank C, Vipin KA. Validated UV spectrophotometric method for estimation of domperidone for dissolution study, Der Pharmacia Lettre, 2015; 7(6):53-58.
11. Pradeep S, Vikash KC, Praveen KV, Amit KS, Vijay Kumar Y. Development and validation of uv-visible spectrophotometric method for the determination of levofloxacin in bulk and tablet formulation, International Journal of Research and Development in Pharmacy and Life Sciences, 2015; 4(1):1375-8.
12. Sumanta Mondal, Goluguri Sunil Reddy, Prasenjit Mondal, Vadlapati Sheeba Prathyusha1, Aishwarya P Nair, and Syed Tazib Rahaman. Development and Validation of Few UV Spectrophotometric Methods for the Determination of Valganciclovir in Bulk and Pharmaceutical Dosage Form Pharm Methods, 2018; 9(2):64-68.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).